Pulmatrix, Inc. (PULM)
About Pulmatrix, Inc.
Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $7.8M
- Net income
- -$5.2M
- Total assets
- $4.1M
- Market cap
- $4.9M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $5.2M
- Operating income
- -$5.2M
- Income tax
- $0
- Net income
- -$5.2M
- EPS (basic)
- $-1.41
- EPS (diluted)
- $-1.41
Balance sheet
- Total assets
- $4.1M
- Current assets
- $4.1M
- Total liabilities
- $329.0K
- Current liabilities
- $329.0K
- Shareholders’ equity
- $3.8M
Cash flow
- Operating cash flow
- -$5.4M
- Net cash flow
- -$5.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $4.9M
- EPS (diluted)
- $-1.41
- Shares outstanding
- 2.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 21, 2014
Pulmatrix, Inc. (PULM) Stock Price
- Reported a net loss of $5.2M in FY2024.
- Trading 77% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Pulmatrix, Inc..
Write a review
News about Pulmatrix, Inc.
News & sentiment via Polygon.io
Pulmatrix, Inc.: frequently asked questions
Is Pulmatrix, Inc. an American company?
Pulmatrix, Inc. is a US-based company headquartered in Framingham, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Pulmatrix, Inc. headquartered?
Pulmatrix, Inc. is headquartered in Framingham, Massachusetts, United States.
Is Pulmatrix, Inc. publicly traded?
Yes — Pulmatrix, Inc. is a publicly traded company. Its stock trades under the ticker symbol PULM on the NASDAQ.
What does Pulmatrix, Inc. do?
Pulmatrix, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
